Cardiac Science Announces Third Quart...(------ ------- Total ...),Health

Date:11/9/2009

------ ------- Total liabilities and equity $126,434 $170,208 ======== ======== Cardiac Science Corporation and Subsidiaries Condensed Consolidated Statements of Cash Flows (unaudited) (in thousands) Three Months Ended September 30, ------------- 2009 2008 ---- ---- Operating Activities: Net income (loss) $(66,411) $2,564 Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: Stock-based compensation 674 469 Depreciation and amortization 1,595 1,544 Deferred income taxes 43,996 1,493 Changes in operating assets and liabilities, net of businesses acquired: Accounts receivable, net (5,552) (526) Inventories 9 (929) Prepaid expenses and other assets 509 (151) Accounts payable 1,672 (591) Accrued liabilities (672) 1,113 Warranty liability 56 825 AED field initiative liability 18,500 - Deferred revenue 539 555 --- --- Net cash provided by (used in) operating activities (5,085) 6,366
'/>"/>

SOURCE Cardiac Science Corporation Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Related medicine technology :

1. Personalized Medicine - The Genomic Revolution in Cardiac Care
2. FAU Receives Patent for Invention Which Induces and Restores Cardiac Muscle Function
3. Signalife Completes Testing of Modules for Holter and Intra-Cardiac Monitor
4. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
5. Study Shows Vernakalant Hydrochloride is Effective in Conversion to Normal Heart Rhythm in Atrial Fibrillation Patients Following Cardiac Surgery
6. FDA Concludes There is No Increased Risk of Cardiac Events for Patients Treated with omeprazole and NEXIUM(R) (esomeprazole magnesium)
7. Do-It-Yourself Cardiac Bypass Surgery: All You Need is Walking Shoes
8. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
9. Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death
10. DATATRAK and COResearch to Collaborate on Six Cardiac Safety Projects
11. Study Finds PCI Safe, Effective Despite Off-Site Cardiac Surgery